Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors

Next Previous
X
Search
Trial Profile

A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACT 001 (Primary)
  • Indications Anaplastic astrocytoma; Colorectal cancer; Diffuse intrinsic pontine glioma; Glioblastoma; Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Accendatech

    • Most Recent Events

    • 15 Feb 2022 Status changed from recruiting to active, no longer recruiting.
    • 15 Feb 2022 Actual date of last participant enrolled is 31 Dec 2018 according to Australian New Zealand Clinical Trials Registry record.
    • 15 Feb 2022 Planned End Date changed from 21 Apr 2017 to 13 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top